Anders Hasager Boss

This inventor holds 17 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 4 EPO patents, primarily in Diabetes Management. Top assignee: Mannkind Corporation. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anders Hasager Boss. Retrieved from https://idiyas.com/inventor/anders-hasager-boss

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 6)

% Patents Active = 82.4

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 217(Granted Patents)

Company Filing History:

17 out of 286

Mannkind Corporation

patents

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

Ultrarapid Acting Insulin

Diabetes Type 2

Glycemia Control

Glucose Elimination

Metformin

Blood Glucose Management

Insulin Administration

Diabetes Treatment

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12303554 - Use of ultrarapid acting insulin (2025-05-20),

2. 11998591 - Method of treating diabetes type 2 by administering ultrarapid acting insulin (2024-06-04),

3. 11931404 - Use of ultrarapid acting insulin (2024-03-19),

4. 11559569 - Use of ultrarapid acting insulin (2023-01-24),

5. 11013788 - Use of ultrarapid acting insulin (2021-05-25),

6. 10857207 - Method of treating diabetes type 2 by administering ultrarapid acting insulin (2020-12-08),

7. 10772935 - Use of ultrarapid acting insulin (2020-09-15),

8. 10307464 - Use of ultrarapid acting insulin (2019-06-04),

9. 10046031 - Use of ultrarapid acting insulin (2018-08-14),

10. 9943571 - Use of ultrarapid acting insulin (2018-04-17),

11. 9801925 - Potentiation of glucose elimination (2017-10-31),

12. 9597374 - Use of ultrarapid acting insulin (2017-03-21),

13. 9006175 - Potentiation of glucose elimination (2015-04-14),

14. 8623817 - Method of treating diabetes type 2 by administering ultrarapid acting insulin (2014-01-07),

15. 8258095 - Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content (2012-09-04),

Title: Inventor Profile: Anders Hasager Boss

Introduction

Anders Hasager Boss is a prominent inventor based in Princeton, NJ, with a significant impact in the field of diabetes treatment. With an impressive portfolio of 17 patents, he has contributed valuable innovations that aim to enhance the management of hyperglycemia.

Latest Patents

Among his notable recent patents, Anders has developed methods for treating hyperglycemia using ultrarapid acting insulin. His patents disclose improved techniques that involve a combination of ultrarapid acting insulin and insulin glargine. These methods suggest prandial administration of the ultrarapid insulin and the administration of a first dose of insulin glargine within six hours of waking, providing a revolutionary approach to diabetes management.

Career Highlights

His career is closely tied to Mannkind Corporation, a leading organization in innovative diabetes therapeutics. Through his work, he has continually pushed the boundaries of diabetes treatment, emphasizing the importance of timely insulin administration for patients.

Collaborations

Anders collaborates with notable colleagues, including Richard Petrucci and Campbell Howard, contributing to a team that drives advancements in diabetes care. These collaborative efforts have strengthened his research and expanded the potential impact of his inventions.

Conclusion

As an inventor, Anders Hasager Boss exemplifies dedication to improving lives through innovation. His work in developing methods for treating diabetes not only highlights the importance of science and technology in healthcare but also underscores the potential of ultrarapid acting insulin to transform the way diabetes is managed.

Profile summary based on public USPTO records.